RH Herzig

1.4k total citations
17 papers, 1.1k citations indexed

About

RH Herzig is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Genetics. According to data from OpenAlex, RH Herzig has authored 17 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hematology, 8 papers in Public Health, Environmental and Occupational Health and 6 papers in Genetics. Recurrent topics in RH Herzig's work include Hematopoietic Stem Cell Transplantation (9 papers), Acute Lymphoblastic Leukemia research (8 papers) and Acute Myeloid Leukemia Research (7 papers). RH Herzig is often cited by papers focused on Hematopoietic Stem Cell Transplantation (9 papers), Acute Lymphoblastic Leukemia research (8 papers) and Acute Myeloid Leukemia Research (7 papers). RH Herzig collaborates with scholars based in United States, Canada and France. RH Herzig's co-authors include Gale Rp, MM Horowitz, Éliane Gluckman, Dicke Ka, K Atkinson, J. C. Biggs, H. G. Prentice, GL Phillips, A Marmont and BM Camitta and has published in prestigious journals such as Blood, Transplantation and Bone Marrow Transplantation.

In The Last Decade

RH Herzig

17 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
RH Herzig United States	13	884	341	254	238	121	17	1.1k
MR O’Donnell United States	16	982 1.1×	405 1.2×	358 1.4×	208 0.9×	150 1.2×	25	1.4k
PM Parker United States	12	833 0.9×	374 1.1×	383 1.5×	160 0.7×	200 1.7×	21	1.2k
AP Nademanee United States	19	1.1k 1.2×	510 1.5×	355 1.4×	182 0.8×	126 1.0×	27	1.4k
AJ Barrett United States	13	963 1.1×	327 1.0×	442 1.7×	188 0.8×	422 3.5×	26	1.3k
DW Beelen Germany	14	750 0.8×	171 0.5×	178 0.7×	142 0.6×	262 2.2×	18	877
JM Rowe United States	10	551 0.6×	174 0.5×	222 0.9×	148 0.6×	89 0.7×	13	771
Jean Paul Vernant France	13	665 0.8×	311 0.9×	191 0.8×	120 0.5×	122 1.0×	25	863
N Gratecos France	13	704 0.8×	193 0.6×	306 1.2×	191 0.8×	230 1.9×	46	1.2k
MT Van Lint Italy	16	718 0.8×	327 1.0×	246 1.0×	142 0.6×	331 2.7×	30	1.1k
E.D. Agura United States	13	753 0.9×	172 0.5×	200 0.8×	172 0.7×	307 2.5×	17	981

Countries citing papers authored by RH Herzig

Since Specialization

Citations

This map shows the geographic impact of RH Herzig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by RH Herzig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites RH Herzig more than expected).

Fields of papers citing papers by RH Herzig

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by RH Herzig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by RH Herzig. The network helps show where RH Herzig may publish in the future.

Co-authorship network of co-authors of RH Herzig

This figure shows the co-authorship network connecting the top 25 collaborators of RH Herzig. A scholar is included among the top collaborators of RH Herzig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with RH Herzig. RH Herzig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

1.

Leventhal, Joseph R., Michaël Abécassis, Joshua Miller, et al.. (2012). A Phase 2 Clinical Trial of Donor Specific Tolerance Induction in Recipients of HLA Disparate Living Donor Kidney Allografts by Donor Stem Cell Infusion. Transplantation. 94(10S). 148–148. 3 indexed citations

2.

Bahceci, Erkut, Scott D. Rowley, Joseph P. McGuirk, et al.. (2007). 306: Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft-vs-host disease (aGVHD). Biology of Blood and Marrow Transplantation. 13(2). 111–111. 2 indexed citations

3.

Fay, Joseph W., Don A. Stevens, RH Herzig, et al.. (2000). Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group. Bone Marrow Transplantation. 25(8). 853–859. 77 indexed citations

4.

Rozmán, C, Enric Carreras, Chongsheng Qian, et al.. (1996). Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia.. PubMed. 17(1). 75–80. 69 indexed citations

5.

Gale, Robert Peter, Thomas Büchner, M-J Zhang, et al.. (1996). HLA-identical sibling bone marrow transplants vs chemotherapy for acute myelogenous leukemia in first remission.. PubMed. 10(11). 1687–91. 32 indexed citations

6.

Goldman, JM, Richard Szydlo, MM Horowitz, et al.. (1993). Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase [see comments]. Blood. 82(7). 2235–2238. 118 indexed citations

7.

Goldman, JM, Richard Szydlo, MM Horowitz, et al.. (1993). Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase [see comments]. Blood. 82(7). 2235–2238. 95 indexed citations

8.

Horowitz, MM, Donna Przepiorka, RE Champlin, et al.. (1992). Should HLA-identical sibling bone marrow transplants for leukemia be restricted to large centers? [see comments]. Blood. 79(10). 2771–2774. 43 indexed citations

9.

Barrett, AJ, MM Horowitz, RC Ash, et al.. (1992). Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 79(11). 3067–3070. 6 indexed citations

10.

Horowitz, MM, Donna Przepiorka, RE Champlin, et al.. (1992). Should HLA-identical sibling bone marrow transplants for leukemia be restricted to large centers? [see comments]. Blood. 79(10). 2771–2774. 34 indexed citations

11.

Horowitz, Mary M., K Atkinson, J. C. Biggs, et al.. (1992). Second HLA-identical sibling transplants for leukemia recurrence.. PubMed. 9(4). 269–75. 128 indexed citations

12.

Phillips, GL, DE Reece, JD Shepherd, et al.. (1991). High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults. Blood. 77(7). 1429–1435. 66 indexed citations

13.

Phillips, GL, DE Reece, JD Shepherd, et al.. (1991). High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults. Blood. 77(7). 1429–1435. 78 indexed citations

14.

Barrett, AJ, MM Horowitz, Gale Rp, et al.. (1989). Marrow transplantation for acute lymphoblastic leukemia: factors affecting relapse and survival. Blood. 74(2). 862–871. 183 indexed citations

15.

Barrett, AJ, MM Horowitz, Gale Rp, et al.. (1989). Marrow transplantation for acute lymphoblastic leukemia: factors affecting relapse and survival. Blood. 74(2). 862–871. 12 indexed citations

16.

Graham‐Pole, John, BM Camitta, J. Casper, et al.. (1988). Intravenous immunoglobulin may lessen all forms of infection in patients receiving allogeneic bone marrow transplantation for acute lymphoblastic leukemia: a pediatric oncology group study.. PubMed. 3(6). 559–66. 35 indexed citations

17.

Wolff, SN, J. Marion, R.S. Stein, et al.. (1985). High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: a pilot study. Blood. 65(6). 1407–1411. 85 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact